Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-20 · accession 0000950170-25-110979 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-22 | 2025-08-20 | NTLA | CHASE WILLIAM J | Dir | P - Purchase | $10.03 | +100.0K | 134.7K | +288% | +$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-20 | P | A | 100,000 | $10.03 | 134,693 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price. |